Tandem high-dose chemotherapy with topotecan –thiotepa–carboplatin and melphalan–etoposide–carboplatin regimens for pediatric high-risk brain tumors
ConclusionsAlthough tandem HDC/auto-SCT with TTC/MEC regimens showed promising survival rates, treatment modifications are warranted to reduce toxicities. The survival rates with relapsed brain tumors were unsatisfactory despite HDC/auto-SCT, and further study is needed.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Children | Medulloblastoma | Neurology | Pediatrics | Pineoblastoma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants